Currently Viewing:
American Diabetes Association (ADA) 2017
Dr Alan Carter on Biosimilars in the Insulin Market
July 27, 2017
Dr Eda Cengiz on New Technologies in Diabetes Management
July 26, 2017
Robby Booth of Glytec Discusses the Importance of Data-Sharing Capabilities
July 24, 2017
Dr Andrew Rhinehart: Improving Intermediate Outcomes in Diabetes Research
July 20, 2017
WellDoc Data Offer Promise for Integrating Diabetes Data Into Workflow
July 17, 2017
Dr Alan Carter on the Steps to Managing Rising Insulin Costs
July 17, 2017
Dr Eda Cengiz Discusses the Future of Diabetes Management
July 13, 2017
Nina Brown-Ashford: DPP Will Improve Care and Costs for Prediabetes Patients
July 06, 2017
Dr Alan Carter on Increasing Insulin Costs
July 04, 2017
Dr William Polonsky on Diabetes Patients' Treatment Satisfaction and Insulin Adherence
June 29, 2017
Dr Eda Cengiz on Improvements in Closed-Loop Systems
June 26, 2017
Currently Reading
With Glytec, Hospital Moves to Basal-Bolus Insulin, Saves $9.7 Million
June 21, 2017
Sanofi Presents New Results for Insulin GLP-1 Combo Soliqua
June 13, 2017
Dr Bruce Neal Discusses Canagliflozin's Potential for Heart Failure Prevention
June 13, 2017
Dr Eda Cengiz Explains Artificial Pancreas Systems' Implications for Patients and Clinicians
June 13, 2017
CGM "Debate" Finds Benefits, Barriers to Uptake for Type 2 Diabetes
June 12, 2017
CANVAS Finds Lower Risk of CV Events for Invokana
June 12, 2017
Phase 3 Results Show Lower A1C for Ertugliflozin, Combined With Metformin and With Sitagliptin
June 12, 2017
Heart Failure Needs More Attention in Diabetes Drug Trials, Expert Says
June 11, 2017

With Glytec, Hospital Moves to Basal-Bolus Insulin, Saves $9.7 Million

Mary Caffrey
The move to quality ratings will put more pressure on hospitals to find ways to improve the standard of care while cutting costs.
A decade ago, the American Diabetes Association (ADA) called for hospitals to shift from sliding scale to subcutaneous basal-bolus insulin therapy for non-critically ill patients, but change has been slow in coming. Fear of hypoglycemia and concerns that staff would not be able to keep up with dosing demands of basal-bolus kept hospitals from upgrading to the standard of care.

Glytec, Inc, had previously presented data that show its electronic glycemic management system (eGMS) offers hospitals a way to meet the basal-bolus standard, reducing the number of days patients were out of range. At the recent 77th Scientific Sessions of the ADA, Glytec presented the bottom line: the electronic system not only improves glycemic control, but it also saves time and money.

Data presented came from Kaweah Delta Medical Center in Tulare County, California, where 13.2% of the county has diabetes. The hospital had struggled to convert to basal-bolus insulin, but did so with help from the electronic-guided insulin dosing system, known as Glucommander.

Researchers matched 1039 patients who received usual care in 2015 with 3200 patients treated during the first year after the switch to eGMS (March 2016 to March 2017). According to the results:

  • Savings from 2434 fewer events in the first year totaled $7,141,356.
  • Savings in average length of stay totaled $2,579,200 (7.18 days vs 5.51 days).
  • Percentage of patients <70 mg/dL: 30.31% for usual care vs 20.10% for Glucommander.
  • Use of the Glucommander resulted in a reduction of 69,256 insulin dose adjustments during the first year, which were otherwise required when manually titrating daily basal-bolus insulin.
  • The calculated time saved per prescribed per patient: 199.5 minutes.
  • The calculated time saved per shift: 30 minutes.
Before the hospital started using the Glytec system, basal-bolus insulin was only used 5% of the time—afterward, the situation was reversed, and basal-bolus was used 96% of the time. Raymie McFarland, vice president of Quality Initiatives at Glytec, said these results are noteworthy given how much the hospital had struggled to make the switch to basal-bolus insulin before engaging Glytec.

While basal-bolus is the standard of care, “It’s difficult to do this for every patient with no endocrinology support,” he said.

The arrival of the Medicare Access and CHIP Reauthorization Act (MACRA), which will bring greater importance to quality ratings, will make it more important than ever for hospitals to find ways to achieve ADA standards without relying on extra manpower. As a practical matter, there aren’t enough endocrinologists to meet demand, due to lagging incomes and a rise in the number of people who need a specialist.

“As the market moves toward value-based reimbursement, we’re there—we’re ready for it,” said Andrew S. Rhinehart, MD, FACP, CDE, BC-ADM, CDTC. Glytec’s system can assist providers with glycemic management at all points on the continuum of care.

Robby Booth, senior vice president of Research and Development, points outs a distinguishing feature: Glucommander can interact with major electronic health record systems, a hurdle that has kept many digital providers from making headway. (Glytec has reported case studies involving integration with EPIC.)

“After 11 years, we’re an overnight success,” Booth said.

Reference

Newsom R, Patty C, Camarena E, Gray T, Sawyer R. Safely Eliminating Sliding Scale thorugh a hospital wide conversion to basal/bolus insulin vs implementation of an electronic glycemic management system. Presented at the 77th Scientific Sessions of the American Diabetes Association, San Diego, California. Abstract 133-LB.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!